Trifecta Research Study
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Sept 2025
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Hormone Replacement Therapy (HRT)
- Magnetic Resonance Therapy (MeRT)
- ibogaine with magnesium treatment
- 5-MeO-DMT
- Record updated
- 22 August 2025
- Why it stopped
- Study is being conducted externally.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- At least 18 years of age
- Sponsored by SOC-F Program
Who cannot take part
- Refusal to taper off of selective serotonin reuptake inhibitor (SSRI) medication
- Diagnosis of Schizophrenia, Bipolar I or II disorder for which patient has been hospitalized or medicated, Depersonalization and/or Derealization Disorder
- Cerebellar dysfunction, Epilepsy, Psychosis or acute confusional state, Dementia
- History of heart failure or hypertrophic heart
- Active blood clots (e.g., Pulmonary embolism, Deep vein thrombosis)
- Major respiratory conditions (e.g., Emphysema, Cystic fibrosis)
- Severe chronic gastrointestinal issues (e.g., bleeding ulcer, leaky gut syndrome)
- Prolonged corrected QT interval (QTc) Interval (450ms in males; 470ms in females)
- Abnormal blood test results (e.g., potassium or magnesium outside normal range)
- Within 6 months of surgeries
- Impaired kidney or liver function
Where in United States
- Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, United States
About the trial
What the trial wants to find out
The Special Operations Care-Fund (SOC-F) will sponsor the application of four treatments - hormone replacement, magnetic resonance brain stimulation, ibogaine, and 5-Meo-DMT - to Special Operations Forces veterans with a history of combat deployments, traumatic brain injury, and problems with mental health and cognitive functioning. An observational study will be conducted in parallel by the Johns Hopkins Center for Psychedelic and Consciousness Research to determine the effectiveness and safety of each treatment, primarily through measuring post-treatment changes in PTSD symptoms and cognitive functioning.
The 2 groups in the trial
- Individuals in this arm will undergo HRT, then Ibogaine and 5-MeO treatment, and then MeRT therapy.Treatment being tested
Treatment: Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, and 5-MeO-DMT
- Individuals in this arm will undergo HRT, then MeRT therapy, and then Ibogaine and 5-MeO-DMT.Existing treatment, for comparison
Treatment: Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, and 5-MeO-DMT
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Trifecta Research Study: Examining Hormone Replacement Therapy, Magnetic e-Resonance Therapy, Ibogaine, and 5-MeO-DMT in the Treatment of Posttraumatic Stress Disorder and Traumatic Brain Injury-related Cognitive Symptoms
- Record updated
- 22 August 2025